Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00664
|
|||||
| Drug Name |
Trifluoperazine
|
|||||
| Synonyms |
10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Apo-Trifluoperazine; Apo-trifluoperazine (TN); Calmazine; Eskazine; Eskazine (TN); Eskazinyl (TN); Fluoperazine; Flurazine; Jatroneural (TN); Modalina; Modalina (TN); NCI17474; Novo-Trifluzine; PMS Trifluoperazine; RP 7623; SKF 5019; Stelazine; Stelazine (*Dihydrochloride*); Stelazine (TN); Stelazine Concentrate; Stellazine; TFP; Terfluzine (TN); Trifluoperaz (TN); Trifluoperazin; Trifluoperazina; Trifluoperazina [INN-Spanish]; Trifluoperazina [Italian]; Trifluoperazine (INN); Trifluoperazine HCl; Trifluoperazine [INN:BAN]; Trifluoperazine dihydrochloride; Trifluoperazinum; Trifluoperazinum [INN-Latin]; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Trifluoromethylperazine; Trifluoroperazine; Trifluoroperazine dihydrochloride; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Tripfluoperazine Hydrochloride; Triphtazin; Triphtazine; Triphthasine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
| Generalized non-psychotic anxiety [ICD11: 6B00] | Approved | [1] | ||||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H24F3N3S
|
|||||
| Canonical SMILES |
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
|
|||||
| InChIKey |
ZEWQUBUPAILYHI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 117-89-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 407.5 | Topological Polar Surface Area | 35 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10319712
, 10505141
, 11110644
, 11110645
, 11120338
, 11120826
, 11121314
, 11121780
, 11122260
, 11336018
, 11361257
, 11362944
, 11363562
, 11364843
, 11365506
, 11366124
, 11367405
, 11368068
, 11368686
, 11369967
, 11371059
, 11371060
, 11372247
, 11373007
, 11373669
, 11373974
, 11375567
, 11376230
, 11376848
, 11378135
, 11405822
, 11408478
, 11458546
, 11460495
, 11462229
, 11466341
, 11467461
, 11484491
, 11486261
, 11488644
, 11491189
, 11492183
, 11494482
, 4252673
, 5664287
, 602753
, 7890752
, 7980830
, 841996
, 9377
|
|||||
| ChEBI ID |
ChEBI:45951
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Trifluoperazine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.